GlobalData
GlobalData

Beth

Zogenix’s Fintepla projected to reach $872m by 2026 despite recent setback

The FDA recently rejected a marketing application for Zogenix’s Fintepla, an anti-epileptic drug candidate for Dravet syndrome. Magdalene Crabbe, Neurology and Ophthalmology Analyst at GlobalData, a leading data and analytics company, discusses the revelation: “The impact of this setback is not necessarily catastrophic. Fintepla is still at the pre-registration stage in the EU and in […]
Read more

Debenhams saved from hands of Mike Ashley but needs more cash to safeguard its future

Following today’s news (Tuesday 9 April) that Debenhams has fallen into administration, Sofie Willmott, Senior Retail Analyst at GlobalData, a leading data and analytics company, offers her view: “The cash injection from the new owners will not be enough to turn around the failing department store’s fortunes. Although Sergio Bucher’s Redesigned strategy, announced almost two years […]
Read more

US will contribute 95% of North America’s new-build underground gas storage capacity growth by 2023

The US will drive growth in North America’s new-build underground gas storage industry between 2019 and 2023, contributing around 95% of the working gas capacity growth in the region, according to GlobalData, a leading data and analytics company. The company’s report: ‘Underground Gas Storage Industry Outlook in North America to 2023 – Capacity and Capital […]
Read more

Louisiana achieves major discount from Gilead’s subsidiary through Hepatitis C procurement model

Louisiana’s Department of Health recently announced that Gilead’s subsidiary Asegua Therapeutics has been selected as the pharmaceutical company for hepatitis C procurement model. Arafa Salam, PhD, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the cost savings realized by this innovative procurement strategy: “The strong competition for patient share […]
Read more

UCB’s Cimzia US approval for nr-axSpA places company ahead of competitive biologic space

The approval of UCB’s Cimzia marks the first anti-tumor necrosis factor biologic therapy for non-radiographic axial spondyloarthritis (nr-axSpA) patients in the US, having been already approved for the condition in Europe. Antoine Grey, MBiochem, Immunology Analyst at GlobalData, a leading data and analytics company, offers his view: “UCB’s efforts to expand into a patient population […]
Read more

Kellogg’s cookie sale part of an emerging trend for portfolio consolidation

Following the news that Kellogg Company has reached an agreement to sell Keebler Cookies and other related businesses to Ferrero, Richard Parker, Principle Consumer Analyst at GlobalData, a leading data and analytics company, offers his view on this latest development: “Kellogg’s divestiture reflects an emerging trend for portfolio consolidation and the company’s commitment to focusing on […]
Read more

High fuel prices and overcapacity strike again as WOW Air is added to the long list of recent airline closures

Following the news that WOW Air has ceased operations after failed negotiations to save it, leaving thousands of passengers stranded, Ralph Hollister, Associate Travel & Tourism Analyst at GlobalData, a leading data and analytics company, offers his view: “The closures of smaller sized airlines such as WOW Air come as little surprise. Even major airlines […]
Read more

Dune not the best fit for LK Bennett

Following today’s news (Wednesday 27 March) that Dune has tabled a bid for LK Bennett, Kate Ormrod, Lead Retail Analyst at GlobalData, a leading data and analytics company, offers her view: “While both retailers tap into the premium occasionwear market, footwear specialist Dune and LK Bennett do not seem like an obvious fit, given the latter’s […]
Read more
1 83 84 85 86 87 93